While the life sciences industry in Germany saw an overall decline in 2022, 2023 proved to be a source of improvement. Venture financing increased from USD 725m to USD 841m. However, biotech financing retracted, with both the number and value of rounds decreasing.
In the Biotech – Therapeutics and Diagnostics sector, oncology remains by far the top indication for asset development, with infectiology/parasitology and cardiology coming in second and third. Key activity areas are small molecules (13%), immunotherapy and anti-infectives (11% each).
In addition to Germany’s strong focus on research and development, the medtech sector is one of the most important drivers of innovation in the German life sciences industry. 22% of all medtech companies develop reusable instruments, followed by 11% single-use devices and 10% electromechanical medical devices.
We would like to thank our partners Bio.NRW, BioRN, BIO Deutschland, and GTAI/HEALTH MADE IN GERMANY for their support in producing this report.